乳腺癌术后胸壁及区域淋巴结复发的治疗

本文对我科1985年6月至1988年6月收治的52例乳腺癌术后复发病例进行了分析。全部病例均完成了放射治疗，其中39例与化疗联合。全组病例局部控制率为59．6％，1年及2年生存率分别为80．8％和51.9%，本文结果提示，单纯胸壁复发的病例，预后明显好于胸壁及区域淋巴结同时复发的病例（P＜0．05)，与化疗联合对局部控制率无影响，但能显著提高长期生存率（P＜O．01）。     

GLP实验室资料档案的管理

原始资料系指记载研究工作的原始观察记录和有关文书材料,包括工作记录、各种照片、缩微胶片、缩微复制品、计算机打印资料、磁性载体和自动化仪器记录材料等.档案是指非临床安全性评价研究机构在从事非临床研究以及其它各项活动时直接形成的对机构和社会具有保存价值的各种文字、图表、声像等不同形式的历史记录.档案是安全性评价实践活动的真实记录,是社会的宝贵财富,应由资料档案室集中统一保管.档案工作是非临床安全性评价研究机构管理工作的组成部分,是反映和追溯安全性评价工作真实历史面貌的一项重要工作,是做好非临床研究的重要基础工作之一.     

上海市人群自报健康分布的综合测量(三)

基于经HOPIT模型校正后的上海市嘉定、宝山、金山和崇明4区(县)的人群自报健康资料，应用伤残集中指数进行人群自报健康分布的综合测量研究。结果表明，在样本地区存在收入相关健康不平等，并提示改善低收入人群的经济状况，特别是收入状况对改善健康的重要性。     

欧姆龙 HEM-770A型电子血压计的检测方法

本文介绍了欧姆龙 HEM-770A型电子血压计的实用检测方法及专用插头.     

NP-HPLC测定阿敏-额尔敦中士的宁的含量

目的:建立蒙药阿敏-额尔敦中士宁含量测定方法.方法:采用正相高效液相色谱法.色谱柱为JapanInertsil(SIL 100A-5μm,4.6mm×150mm),流动相为正己烷-二氯甲烷-甲醇-浓氨试液(47.5:47.5:5:0.35),流速1mL·min-1,柱温:30℃,检测波长为254nm.结果:士的宁进样量在0.0918～0.459μg范围内呈良好的线性关系(r=0.9996),平均加样回收率为98.12%,RSD为0.87%.结论:采用正相高效液相色谱法测定士宁含量,方法简便、灵敏、准确,可作为蒙药阿敏-额尔敦的质量控制方法.     

论坛专题报告之二 Employing Industry Standards for System Integration in Digital Radiology Department

１．INTRODUCTIONSincethepastdecade熏RadiologyInformationSystem穴RIS雪andPictureArchivingandCommunicationSys鄄tem穴PACS雪havebeingemployedinanincreasednumberofradiologyde鄄partmentstoimproveprocesspro鄄ductivity熏providebetterqualityofimagingservices熏andreducemedicalerrors．Intherecentyears熏systemin鄄tegrationhasbecomethemajorneedofthehealthcareprovidersworld鄄wide熏todrivethedirectionofthede鄄velopmentofRISandPACStowardsafullyintegrateddigitalradiologyde鄄partment．Openindustrys…     

Repurposing povidone-iodine to reduce the risk of SARS-CoV-2 infection and transmission: a narrative review

BackgroundAccumulating data suggest antiviral effects of povidone-iodine against the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. This narrative review aims to examine the antiviral mechanisms of povidone-iodine, efficacy of povidone-iodine against the SARS-CoV-2 virus, and safety of povidone-iodine to human epithelial cells and thyroid function.MethodsWe searched the electronic databases PubMed, Embase, Cochrane Library, ClinicalTrials.gov and World Health Organization’s International Clinical Trials Registry Platform for articles containing the keywords “povidone-iodine”, “SARS-CoV-2” and “COVID-19” from database inception till 3 June 2021.ResultsDespite in vitro data supporting the anti-SARS-CoV-2 effects of povidone-iodine, findings from clinical studies revealed differences in treatment response depending on study settings (healthy vs. hospitalized individuals), treatment target (nasal vs. oral vs. pharynx), method of administration (oral rinse vs. gargle vs. throat spray) and choice of samples used to measure study endpoints (nasopharyngeal vs. saliva). One large-scale clinical trial demonstrated reduction in the incidence of SARS-CoV-2 infection among participants who administered povidone-iodine 3 times daily during an active outbreak. Povidone-iodine is also used to disinfect the oro-pharyngeal space prior to dental or otolaryngology procedures. Although existing data suggest minimal impact of povidone-iodine on thyroid function, high-quality safety data are presently lacking.ConclusionsPovidone-iodine application to the oropharyngeal space could complement existing non-pharmacological interventions to reduce SARS-CoV-2 infection especially in high exposure settings.

Key messages

• Accumulating data suggest antiviral effects of povidone-iodine against the SARS-CoV-2 virus.
• Findings from clinical studies reveal differences in treatment response depending on study settings, treatment target, method of administration and choice of samples used to measure study endpoints. One large-scale clinical trial observed reduction in the incidence of SARS-CoV-2 infection among participants who administered povidone-iodine 3 times daily during an active outbreak.
• Povidone-iodine application to the oropharyngeal space could complement existing non-pharmacological interventions to reduce SARS-CoV-2 infection especially in high exposure settings.

     

Patients' experiences across the trajectory of atrial fibrillation: A qualitative systematic review

AimThis study aimed to synthesize qualitative evidence on experiences of patients with atrial fibrillation (AF) during the course of diagnosis and treatment. We addressed three main questions: (a) What were the experiences of patients with AF during the course of diagnosis and treatment? (b) How did they respond to and cope with the disease? (c) What were the requirements during disease management?DesignIn this study, qualitative evidence synthesis was performed using the Thomas and Harden method.Data SourcesElectronic databases, including PubMed, the Cochrane Library, Embase, Web of Science, Cumulative Index to Nursing and Allied Health Literature, the China Biomedical Database, the WanFang Database, Chinese National Knowledge Infrastructure and VIP, were searched. The databases were searched from inception to August 2021.Review MethodsTwo researchers independently selected studies using qualitative assessment and review instruments for quality evaluation and thematic synthesis for the data analysis.ResultsA total of 2627 studies were identified in the initial search and 15 studies were included. Five analytical themes were generated: ‘Diagnosing AF’; ‘The impact of AF on the patients’; ‘Self‐reorientation in the therapeutic process’; ‘Living with AF and QoL’; and ‘External support to facilitate coping strategies.’ConclusionsOur findings point out unique experiences of patients across the trajectory of AF related to delayed diagnosis, feelings of nonsupport, disappointment of repeated treatment failure and multiple distress associated with unpredictable symptoms. Future research and clinical practice are expected to improve the quality of medical diagnosis and treatment, optimize administrative strategy and provide diverse health support for patients with AF.ImpactUnderstanding the experiences and needs of patients with AF in the entire disease process will inform future clinical practice in AF integrated management, which would be helpful in improving the professionalism and confidence of healthcare providers. In addition, our findings have implications for improving the effectiveness of AF diagnostic and treatment services.Patient or Public ContributionThis paper presents a review of previous studies and did not involve patients or the public.     

植物源抗菌活性成分的研究进展

介绍近年来国内外研究发现的多种已知结构类型及新结构类型的植物源抗菌活性成分。简要归纳了其抗菌活性及其相应的MIC值。同时对构效关系进行了分析。并对其中抗菌活性较强。具有进一步研究开发价值的化合物及结构类型进行了概括。     

Isoflavonoids from Astragalus mongholicus protect PC12 cells from toxicity induced by L-glutamate

lsoflavonoids, formononetin, 9,10-dimethoxypterocarpan 3-O-beta-D-glucoside, ononin, calycosin 7-O-glc and calycosin, were isolated from the roots of Astragalus mongholicus Bunge (Leguminosae). The neuroprotective roles and direct antioxidant effects of these isoflavonoids were investigated by using PC12 cell model and DPPH (1,1-diphenyl-2-picrylhydrazyl) assay. Formononetin, ononin and calycosin were found inhibiting glutamate-induced cell injury, with an estimated 50% effective concentration (EC50) of 0.027 microg/ml, 0.047 microg/ml and 0.031 microg/ml, respectively. Pretreatment with them increased the activities of antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), and prevented the release of lactate dehydrogenase (LDH) in glutamate-injured PC12 cells. On the other hand, calycosin 7-O-glc and calycosin showed more scavenging activity to DPPH radicals than formononetin in the cell-free system. The inconsistency between the neuroprotective capabilities of isoflavonoids and their directly scavenging activity to DPPH radicals indicated that formononetin, ononin and calycosin probably depended on increasing endogenous antioxidant and stabilizing the cells' membrane structures to inhibit the cell damage induced by glutamate.